盘前暴涨超8%！减肥药卖爆！药王礼来Q4业绩超预期！2026年营收指引超预期！

Core Viewpoint - Eli Lilly has significantly outperformed market expectations in Q4 revenue and profit, driven by the explosive sales of GLP-1 weight loss drugs, indicating a strong competitive position against Novo Nordisk in the weight loss drug market [1][3]. Financial Performance - In Q4, Eli Lilly reported revenue of $19.3 billion, a 43% year-over-year increase, surpassing analyst expectations of $18 billion [5]. - Non-GAAP EPS for Q4 was $7.54, up 42% year-over-year, exceeding market expectations of $6.73 [5]. - The strong performance is attributed to the robust demand for diabetes drug Mounjaro and weight loss drug Zepbound, with Zepbound's total prescriptions surpassing Novo Nordisk's Wegovy [5]. Future Outlook - Eli Lilly projects 2026 revenue between $80 billion and $83 billion, significantly above Wall Street's average expectation of $77.7 billion [7]. - Adjusted EPS is expected to be between $33.50 and $35.00, also exceeding analyst expectations of $33.08 [7]. - The company is leveraging its patent protection, aggressive capacity expansion, and upcoming oral formulations to maintain a competitive edge [7]. Key Products - Mounjaro and Zepbound together contributed over 60% of total revenue in Q4, with combined revenue exceeding $11.6 billion [9]. - Mounjaro's Q4 revenue reached $7.41 billion, a staggering 110% increase year-over-year, while Zepbound achieved $4.26 billion, a 123% increase [12]. Sales Strategy - Eli Lilly's growth is driven by volume, with global product sales increasing by 46% in Q4, offsetting a 5% decline in realized prices [12]. - In the U.S. market, sales volume surged by 50%, despite a 7% drop in actual prices, reflecting strategic pricing adjustments to expand patient access [12]. Market Position - Eli Lilly's optimistic outlook starkly contrasts with Novo Nordisk's warning of a potential 13% decline in sales due to intensified price competition [15]. - The company is expected to maintain over 20% growth in 2026, even with a high revenue base of $65.18 billion in 2025 [15]. R&D and Capacity Expansion - Eli Lilly is advancing its pipeline with a focus on convenient administration methods and expanding indications, including an oral weight loss drug awaiting regulatory approval [19]. - The company is investing heavily in production capacity, including a new injection facility in Pennsylvania and a $6 billion active pharmaceutical ingredient plant in Alabama [19]. Financial Metrics - The gross margin is reported at 82.5%, with a non-GAAP margin of 83.2%, benefiting from favorable product mix and improved production costs [20]. - R&D expenses increased by 26% to $3.8 billion, representing 20% of revenue, while SG&A expenses rose by 29% to $3.1 billion, also 20% of revenue [20].